Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
respiratory diseases
Pharma
Insmed forecasts sales of Brinsupri will reach $1B in 2026
Insmed has projected sales of its newly approved respiratory disease drug Brinsupri will achieve sales of "at least" $1 billion in 2026.
Kevin Dunleavy
Feb 19, 2026 11:45am
Insmed's Brinsupri comes up short in rhinosinusitis trial
Dec 18, 2025 11:27am
Moderna-backed campaign takes a shot at boosting vaccine uptake
Oct 22, 2025 12:30pm
Savara's lung disease asset hit with FDA refuse-to-file letter
May 27, 2025 10:35am
Chiesi unveils €430M investment in new Italian inhaler facility
Mar 27, 2025 10:47am
GSK posts COPD win for Nucala as rival nears possible approval
Sep 6, 2024 9:40am
